摘要
目的探讨白细胞介素(IL)-10和IL-6在不同类型淋巴瘤组织与血浆中的表达及其意义。方法收集97例淋巴瘤患者石蜡组织和血浆标本,应用免疫组织化学和酶联免疫吸附试验(ELISA)的方法观察组织与血浆中IL-10和IL-6表达情况。结果IL-10和IL-6在不同类型淋巴瘤组织中皆呈阳性表达,且各亚型之间差异无统计学意义(x2=0.815,x2=0.542,均P〉0.05);IL-10和IL-6分别在肿瘤中的巨噬细胞和血管内皮细胞也有不同程度的阳性表达。淋巴瘤患者血浆IL-10和IL-6水平[(232.57±191.59)pg/ml、(80.70±89.68)Pg/ml]高于健康对照组[(59.12±68.35)Pg/ml、(45.68±33.66)pg/ml],差异有统计学意义(t=6.968,t=2.896,P〈0.05);血浆IL-10和IL-6水平随肿瘤细胞表达强度增强而增强(x2=0.815,x2=0.542,P〈0.05);IL-10和IL-6在淋巴瘤细胞表达强度两者呈正相关(L=0.394,P〈0.05)。结论IL-10和IL-6在淋巴瘤患者淋巴瘤组织和血浆中都有表达,淋巴瘤患者血浆IL—10和IL-6水平高于健康对照组,二者在淋巴瘤的发生、发展中起着一定的作用,可能作为淋巴瘤诊断的辅助指标。
Objective To investigate the expression of IL-10 and IL-6 in tissue and plasma of subtypes lymphoma and its significance. Methods Immunohistochemical technique and enzyme-linked immunosorbent assay (ELISA) were used to assess the expression of IL-10 and IL-6 in 97 cases paraffin tissue and plasma samples from different subtypes of lymphoma. Results Expression of IL-10 and IL-6 was positive in all lymphoma tissue samples, but there is no significant difference among different subtypes lymphoma (x2 = 0.815, X2 = 0.542, P 〉 0.05). Tumor samples were found positive IL-10 and IL-6 expression in macrophages and vascular endothelial cells by immunohistochemistry respectively. Expression of IL-10 and IL-6 in plasma of lymphoma were higher than that in control respectively [(232.57±191.59) pg/ml vs (59.12± 68.35) pg/ml, (80.70±89.68) pg/ml vs (45.68±33.66) pg/ml], with significant difference (t = 6.968, t = 2.896, P 〈0.05). IL-10 and IL-6 plasma levels increased with enhanced expression in lymphoma (X2 = 0.815, X2 = 0.542, P 〈 0.05). Which was found to be correlated with each other (r, = 0.394, P 〈 0.05). Conclusion The expression of IL-10 and IL-6 had been found at various degrees in tissues and plasma of lymphoma. IL-10 and IL-6 in plasma of lymphoma were higher than that in controls. These results showed that IL-10 and IL-6 may cooperate in vivo with lymphoma cell proliferation and infiltrate. IL-6 and IL-10 maybe served as useful indicators for diagnosis of lymphoma.
出处
《白血病.淋巴瘤》
CAS
2012年第1期50-53,共4页
Journal of Leukemia & Lymphoma
基金
基金项目:国家自然科学基金(30860096)